Related Experiment Video
Updated: Jun 2, 2026

Murine Full-thickness Skin Transplantation
Published on: January 2, 2017
Relapse of aplastic anemia responsive to sirolimus combined with cyclosporine
Guangsheng He1, Xiang Zhang, Depei Wu
1Key Laboratory of Thrombosis and Hematostasis of Ministry of Health, Jiangsu Insititute of Hematology, Department of Hematology of First Affiliated Hospital of Soochow University, Suzhou, Jiangsu Province, P.R. China. heguangsheng@medmail.com.cn
Aplastic anemia (AA) is an immune-mediated disease. Although most patients are responsive to immunosuppressive therapy (IST) with a combination of anti-thymocyte globulin (ATG) and cyclosporine (CsA), some patients relapse or are refractory to IST. Sirolimus (rapamysin) inhibits the serine-threonine kinase mammalian target of rapamysin (mTOR), and blocks CsA-resistant and calcium-independent pathways late in the progression of the T-cell cycle. We report two cases of AA which relapsed after CsA and ATG plus CsA, respectively. They achieved transfusion independence after retreatment with sirolimus in combination with a CsA.
Aplastic anemia (AA) is an immune-mediated disease. Although most patients are responsive to immunosuppressive therapy (IST) with a combination of anti-thymocyte globulin (ATG) and cyclosporine (CsA), some patients relapse or are refractory to IST. Sirolimus (rapamysin) inhibits the serine-threonine kinase mammalian target of rapamysin (mTOR), and blocks CsA-resistant and calcium-independent pathways late in the progression of the T-cell cycle. We report two cases of AA which relapsed after CsA and ATG plus CsA, respectively. They achieved transfusion independence after retreatment with sirolimus in combination with a CsA.
Related Concept Videos
Cell-mediated Immune Responses
iPS Cell Differentiation
Immunodeficiency Diseases
There are three main causes of immunodeficiency disorders...
